Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,246

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

Open access
Banwell, Brenda, Bennett, Jeffrey L, Marignier, Romain, Kim, Ho Jin, Brilot, Fabienne, Flanagan, Eoin P, Ramanathan, Sudarshini, Waters, Patrick, Tenembaum, Silvia, Graves, Jennifer S, Chitnis, Tanuja, Brandt, Alexander U, Hemingway, Cheryl, Neuteboom, Rinze, Pandit, Lekha, Reindl, Markus, Saiz, Albert, Sato, Douglas Kazutoshi, Rostasy, Kevin, Paul, Friedemann, Pittock, Sean J, Fujihara, Kazuo, Palace, Jacqueline·2023·The Lancet Neurology
DOI 10.1016/s1474-4422(22)00431-8
Open this paper in CoChat — free account

Abstract

Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder. Based on an extensive literature review and a structured consensus process, we propose diagnostic criteria for MOG antibody-associated disease (MOGAD) in which the presence of MOG-IgG is a core criterion. According to our proposed criteria, MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, and is less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations. MOGAD can present as either a monophasic or relapsing disease course, and MOG-IgG cell-based assays are important for diagnostic accuracy. Diagnoses such as multiple sclerosis need to be excluded, but not all patients with multiple sclerosis should undergo screening for MOG-IgG. These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is essential to define long-term clinical outcomes, refine inclusion criteria for clinical trials, and identify predictors of a relapsing versus a monophasic disease course.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(22)00431-8

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 12

  1. Senanayake, 2019, Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka, J Neurol Neurosurg Psychiatry, 90, 1381
  2. Kaneko, 2017, Clinical, MRI and laboratory features of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated neurologic disease: a study of 259 cases, Mult Scler J, 23, 100
  3. Jitprapaikulsan, 2018, Novel glial targets and recurrent longitudinally extensive transverse myelitis, JAMA Neurol, 75, 892, 10.1001/jamaneurol.2018.0805 · doi:10.1001/jamaneurol.2018.0805
  4. Sechi, 2020, Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies, Mult Scler, 20
  5. Asnafi, 2020, The frequency of longitudinally extensive transverse myelitis in MS: a population-based study, Mult Scler Relat Disord, 37, 10.1016/j.msard.2019.101487 · DOI
  6. Netravathi, 2021, Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder, J Neurol, 268, 1419, 10.1007/s00415-020-10300-z · doi:10.1007/s00415-020-10300-z
  7. Lopez-Chiriboga, 2020, Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder, JAMA Neurol, 77, 1575, 10.1001/jamaneurol.2020.3115 · doi:10.1001/jamaneurol.2020.3115
  8. Macrini, 2021, Features of MOG required for recognition by patients with MOG antibody-associated disorders, Brain, 144, 2375, 10.1093/brain/awab105 · doi:10.1093/brain/awab105
  9. Kwon, 2021, Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability, Neurol Neuroimmunol Neuroinflamm, 9
  10. Pace, 2022, Frequency of MOG-IgG in cerebrospinal fluid versus serum, J Neurol Neurosurg Psychiatry, 93, 334, 10.1136/jnnp-2021-326779 · doi:10.1136/jnnp-2021-326779
  11. Kunchok, 2020, Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients, JAMA Neurol, 77, 257, 10.1001/jamaneurol.2019.3656 · doi:10.1001/jamaneurol.2019.3656
  12. Ducloyer, 2020, MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis, Br J Ophthalmol, 104, 842, 10.1136/bjophthalmol-2019-314845 · doi:10.1136/bjophthalmol-2019-314845

Cited by

See all 1,246

Metadata

Authors
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., Chitnis, T., Brandt, A. U., Hemingway, C., Neuteboom, R., Pandit, L., Reindl, M., Saiz, A., Sato, D. K., Rostasy, K., Paul, F., Pittock, S. J., Fujihara, K., & Palace, J.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2023-03
Volume
22
Issue
3
Pages
268-282
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(22)00431-8
OpenAlex
W4318391603
Cited by
1,246
References
101
FWCI
205.39
Type
journal article
Language
en
Open access
green
Licence
Funders
  • Guthy-Jackson Charitable Foundation
  • Mayo Clinic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. https://app.cochat.ai/papers/10.1016/s1474-4422(22)00431-8
The paper
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., Chitnis, T., Brandt, A. U., Hemingway, C., Neuteboom, R., Pandit, L., Reindl, M., Saiz, A., Sato, D. K., Rostasy, K., . . . Palace, J. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(22)00431-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.